{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "1559b82c",
   "metadata": {},
   "source": [
    "\n",
    "## 25.Molecular RNA Correlates of the SOFA Score in Patients with Sepsis\n",
    "\n",
    " Objective:\n",
    " \n",
    "To identify key regulatory molecules at the RNA level (miRNA and mRNA) that correlate with SOFA score criteria and provide molecular insight into sepsis-induced organ dysfunction.\n",
    "\n",
    "1. Study Design:\n",
    "\n",
    "Subjects:\n",
    "7 patients with septic shock and 6 healthy controls for RNA sequencing (RNAseq).\n",
    "A second cohort (20 septic patients, 5 controls) for RT-qPCR validation.\n",
    "\n",
    "SOFA Scoring:Used to assess organ dysfunction (criteria: hypoxia, neurological dysfunction, hypotension, kidney injury, liver failure, and coagulopathy).\n",
    "\n",
    "2. Molecular Analyses:\n",
    "\n",
    "RNA Sequencing (RNAseq):High-throughput analysis of miRNA and mRNA expression in blood cells.\n",
    "\n",
    "RT-qPCR Validation:Confirmed key miRNA and mRNA findings in an independent cohort.\n",
    "\n",
    "Bioinformatics:Integrated miRNA-mRNA networks to identify molecules specific to SOFA criteria.\n",
    "\n",
    "Pathway enrichment and interaction analyses using Ingenuity Pathway Analysis (IPA).\n",
    "\n",
    "Key Findings:\n",
    "\n",
    "1. Differential Expression:\n",
    "\n",
    "82 miRNAs and 3254 mRNAs were differentially expressed in sepsis patients compared to controls.\n",
    "45% of miRNAs and 50% of mRNAs were upregulated.\n",
    "Identified miRNAs and mRNAs linked to each SOFA criterion.\n",
    "\n",
    "2. Molecules Associated with Specific SOFA Criteria:\n",
    "\n",
    "Hypoxia (PaO2/FiO2 ratio):Upregulated: **VEGFA** (vascular endothelial growth factor A).Downregulated: **IGFBP3** (insulin-like growth factor-binding protein 3).\n",
    "\n",
    "Neurological Dysfunction (Glasgow Coma Scale):Upregulated: **LCN2** (Lipocalin-2), **MMP9** (matrix metallopeptidase 9).\n",
    "\n",
    "miRNAs:**miR-30c-5p, let-7a-5p**.\n",
    "\n",
    "Hypotension and Circulatory Failure:Upregulated: **IL1RN, PPARG** (peroxisome proliferator-activated receptor gamma), **TP53**.\n",
    "\n",
    "miRNAs: **miR-125b-5p, miR-30c-5p**.\n",
    "\n",
    "Kidney Injury (Creatinine increase):Upregulated: **LNC2, ANXA1 (Annexin 1), AKR1B1**.Downregulated: **MYC** (bHLH transcription factor).\n",
    "\n",
    "miRNAs: **miR-92a-3p, let-7a-5p**.\n",
    "\n",
    "Liver Dysfunction (Bilirubin increase):Upregulated: **TLR4, ABCG2**.\n",
    "Downregulated: **GFER**.\n",
    "\n",
    "Coagulopathy (Low platelet count):Upregulated: **PF4, THBS1**. Downregulated: **PDGFB, BCL2**.\n",
    "\n",
    "3. Validation and Clinical Significance:\n",
    "\n",
    "RT-qPCR validated key molecules, confirming their diagnostic relevance.\n",
    "LCN2 and VEGFA were identified as significant markers of sepsis-related organ dysfunction.\n",
    "\n",
    "Protein vs. Gene Level:\n",
    "\n",
    "Gene Level:\n",
    "Focused on RNA expression (miRNA and mRNA) to explore gene regulation.\n",
    "Protein Level:\n",
    "The study does not directly analyze protein levels but references proteins encoded by key mRNAs (e.g., VEGFA, LCN2).\n",
    "\n",
    "Diagnostic and Prognostic Relevance:\n",
    "\n",
    "Diagnostic Role:\n",
    "miRNA and mRNA changes (e.g., LCN2, VEGFA) correlate with organ dysfunction, making them potential diagnostic markers for specific SOFA components.\n",
    "\n",
    "Prognostic Role:\n",
    "Differential expression of certain molecules (e.g., TLR4, IL1RN) linked to sepsis severity and outcomes.\n",
    "\n",
    "\n",
    "## 26. Identification of an Immune-Related Gene Diagnostic Model and Potential Drugs in Sepsis Using Bioinformatics and Pharmacogenomics Approaches\n",
    "\n",
    "Objective:\n",
    "\n",
    "To identify immune-related genes with diagnostic potential in sepsis and explore potential drug targets using bioinformatics and pharmacogenomics approaches.\n",
    "\n",
    "\n",
    "1. Data Collection and Preprocessing:\n",
    "\n",
    "Datasets:\n",
    "Gene Expression Omnibus (GEO) datasets: GSE69063, GSE154918 (training sets), and GSE28750 (validation set).\n",
    "Data included blood samples from patients with sepsis and healthy controls.\n",
    "Batch Effect Removal:Used the \"ComBat\" function to normalize data for consistent analysis.\n",
    "\n",
    "2. Differentially Expressed Genes (DEGs):\n",
    "\n",
    "DEGs were identified using the \"limma\" package, with thresholds:\n",
    "False discovery rate (FDR) < 0.05.\n",
    "Fold change > 1.\n",
    "\n",
    "3. Weighted Gene Co-Expression Network Analysis (WGCNA):\n",
    "\n",
    "Constructed gene co-expression networks to identify modules highly correlated with sepsis.\n",
    "\n",
    "4. Protein-Protein Interaction (PPI) Network:\n",
    "\n",
    "93 immune-related key genes were identified by intersecting DEGs, immune-related genes, and hub modules.\n",
    "5 hub genes were identified using centrality measures from PPI analysis.\n",
    "\n",
    "5. Diagnostic Model Construction:\n",
    "\n",
    "Built three classification models (Random Forest, Support Vector Machine, Decision Tree) using hub gene expression data.\n",
    "Receiver operating characteristic (ROC) curves were used to assess model performance.\n",
    "\n",
    "6. Drug Prediction:\n",
    "\n",
    "Drug-Gene Interaction Database (DGIdb) was used to identify drugs targeting proteins encoded by hub genes.\n",
    "\n",
    "7. Validation:\n",
    "\n",
    "Reverse transcription-polymerase chain reaction (RT-PCR) validated hub gene expression in blood samples from sepsis patients and healthy controls.\n",
    "\n",
    "Key Findings:\n",
    "\n",
    "1. Immune-Related Hub Genes:\n",
    "\n",
    "Upregulated Genes:\n",
    "\n",
    "**Interleukin 10 (IL10).\n",
    "Lipocalin-2 (LCN2).\n",
    "Downregulated Genes:\n",
    "Interleukin 7 receptor (IL7R).\n",
    "CD40 ligand (CD40LG).\n",
    "CD28 molecule (CD28).**\n",
    "\n",
    "2. Diagnostic Model:\n",
    "\n",
    "All models demonstrated strong performance in distinguishing sepsis patients from controls.\n",
    "Highest performance: Support Vector Machine (AUC > 0.95).\n",
    "\n",
    "3. Immune Infiltration Analysis:\n",
    "\n",
    "Increased infiltration: activated dendritic cells, monocytes, and macrophages.\n",
    "Reduced infiltration: immature B cells and T follicular helper cells.\n",
    "Gene-Immune Cell Relationships:\n",
    "\n",
    "**LCN2**: positively associated with activated dendritic cells.\n",
    "**IL7R, CD28**: negatively associated with activated dendritic cells.\n",
    "**IL10**: negatively associated with immature B cells.\n",
    "\n",
    "4. Functional Enrichment:\n",
    "\n",
    "Key pathways:\n",
    "T cell receptor signaling (CD28).\n",
    "NF-kappa B signaling (CD40LG).\n",
    "JAK-STAT signaling (IL10).\n",
    "\n",
    "5. Drug Prediction:\n",
    "\n",
    "IL10 was targeted by 17 drugs, including cyclosporine.\n",
    "CD40LG and CD28 were targeted by 6 and 11 drugs, respectively, including aldesleukin.\n",
    "\n",
    "6. Validation:\n",
    "\n",
    "RT-PCR confirmed gene expression trends in blood samples from sepsis patients.\n",
    "\n",
    "Protein vs. Gene Level:\n",
    "\n",
    "The study primarily focused on gene-level investigations, identifying differential mRNA expression and validating it with RT-PCR.\n",
    "Protein-level analysis was inferred for drug interactions but not directly measured.\n",
    "\n",
    "Diagnostic and Prognostic Relevance:\n",
    "\n",
    "Diagnostic Role:\n",
    "\n",
    "The identified hub genes (**IL10, LCN2, IL7R, CD40LG, CD28**) serve as reliable diagnostic markers for sepsis.\n",
    "\n",
    "Prognostic Role:LCN2 showed significant differences between shock and non-shock patients, suggesting a role in predicting sepsis severity.\n",
    "\n",
    "\n",
    "Upregulated Genes:Interleukin 10 (IL10).Lipocalin-2 (LCN2).\n",
    "\n",
    "Downregulated Genes:Interleukin 7 receptor (IL7R).CD40 ligand (CD40LG).CD28 molecule (CD28).\n",
    "\n",
    "\n",
    "## 27. Persistent sepsis-induced transcriptomic signatures in signaling pathways of peripheral blood leukocytes: A pilot study\n",
    "\n",
    "Objective:\n",
    "\n",
    "To investigate sepsis-induced transcriptomic alterations in peripheral blood leukocytes, focusing on signaling pathways governing immune responses. The study also examines the persistence of these transcriptomic changes six months after recovery, providing insights into post-sepsis immunosuppression.\n",
    "\n",
    ":\n",
    "1. Study Design:\n",
    "\n",
    "Cohorts:\n",
    "Group I (Infection): 4 patients with systemic bacterial infections.\n",
    "Group S (Sepsis): 4 patients with sepsis, including blood sampling during acute sepsis.\n",
    "Group SR (Sepsis Recovery): Follow-up sampling six months post-recovery from the same sepsis cohort.\n",
    "\n",
    "Exclusions:\n",
    "Patients with autoimmune, malignant, or chronic inflammatory diseases.\n",
    "\n",
    "2. Transcriptomic Analysis:\n",
    "\n",
    "Sample Collection:\n",
    "Peripheral blood leukocytes collected during infection, sepsis, and post-recovery.\n",
    "\n",
    "RNA Extraction and cDNA Synthesis:\n",
    "RNA extracted using the MagMAX RNA Isolation Kit.\n",
    "Reverse transcription to cDNA using the SuperScript VILO cDNA Synthesis Kit.\n",
    "\n",
    "Gene Expression Profiling:Analyzed 573 signaling genes using the TaqMan OpenArray Human Signal Transduction Panel.\n",
    "Results normalized using Î”CT methods.\n",
    "\n",
    "Validation:\n",
    "qPCR validation for selected genes: CXCL10, IRS1, JUN, TLR7, WNT5B.\n",
    "\n",
    "3. Bioinformatics and Statistical Analysis:\n",
    "\n",
    "Principal Component Analysis (PCA):Evaluated distinct transcriptomic signatures for infection, sepsis, and recovery phases.\n",
    "\n",
    "Gene Expression Analysis:Differentially expressed genes identified with fold-change thresholds >2 and adjusted p-values <0.05.\n",
    "\n",
    "Pathway Analysis:KEGG pathway enrichment using the g:Profiler software.\n",
    "\n",
    "Protein-Protein Interaction:STRING database analysis for pathway interconnections.\n",
    "\n",
    "Key Findings:\n",
    "\n",
    "1. Transcriptomic Alterations in Sepsis:\n",
    "\n",
    "Pro-Inflammatory Changes:\n",
    "Upregulation of pro-inflammatory genes:CXCL10, MMP9, CCNA1, MAP2K6, and MAPK14.\n",
    "\n",
    "Increased expression of inflammatory mediators such as S100 calcium-binding proteins (S100A12, S100A8, S100A9) and matrix metalloproteinases.\n",
    "\n",
    "Immunosuppressive Signals:\n",
    "\n",
    "Upregulated anti-inflammatory and immunosuppressive genes:SOCS1, SOCS3, IL10, GADD45A, GRB10.\n",
    "\n",
    "Repression of lymphocyte activation and survival markers:BCL2, FASLG, LEF1, TCF7, WNT7A.\n",
    "\n",
    "2. Long-Term Transcriptomic Signatures:\n",
    "\n",
    "Nearly 30% of sepsis-related transcriptomic changes persisted six months post-recovery.\n",
    "\n",
    "Sustained repression of key signaling pathways:\n",
    "Wnt signaling, mTOR pathway, JAK/STAT pathway, Toll-like receptor signaling.\n",
    "Persistent upregulation of CXCL10 and downregulation of JUN during recovery.\n",
    "\n",
    "3. Pathway Insights:\n",
    "\n",
    "Sepsis-induced dysregulation affects both pro-inflammatory (TNF, IL-17) and anti-inflammatory (TGF-Î²) pathways.\n",
    "Long-term repression of pathways critical for lymphocyte development and survival contributes to post-sepsis immunosuppression.\n",
    "\n",
    "Protein vs. Gene Level:\n",
    "\n",
    "The study focuses on gene-level transcriptomic changes, with no direct protein-level validation of signaling pathways.\n",
    "\n",
    "Diagnostic and Prognostic Relevance:\n",
    "\n",
    "Diagnostic Value:Pro-inflammatory markers (e.g., CXCL10, MMP9) and anti-inflammatory signals (IL10, SOCS3) can potentially serve as biomarkers for sepsis identification and immune dysregulation.\n",
    "\n",
    "Prognostic Role:Long-term transcriptomic alterations, particularly sustained immunosuppressive signatures, may predict susceptibility to infections or post-sepsis complications.\n",
    "\n",
    "\n",
    "Pro-inflammatory markers and anti-inflammatory signals identified as potential biomarkers for sepsis and immune dysregulation include the following:\n",
    "\n",
    "Pro-inflammatory markers:\n",
    "\n",
    "CXCL10 (CXC motif chemokine ligand 10).\n",
    "MMP9 (Matrix metallopeptidase 9).\n",
    "CCNA1 (Cyclin A1).\n",
    "MAP2K6 (Mitogen-activated protein kinase kinase 6).\n",
    "MAPK14 (Mitogen-activated protein kinase 14).\n",
    "S100A12 (S100 calcium-binding protein A12).\n",
    "S100A8 (S100 calcium-binding protein A8).\n",
    "S100A9 (S100 calcium-binding protein A9).\n",
    "\n",
    "Anti-inflammatory signals:\n",
    "\n",
    "IL10 (Interleukin 10).\n",
    "SOCS1 (Suppressor of cytokine signaling 1).\n",
    "SOCS3 (Suppressor of cytokine signaling 3).\n",
    "GADD45A (Growth arrest and DNA damage-inducible alpha).\n",
    "GRB10 (Growth factor receptor-bound protein 10).\n",
    "BCL2 (B-cell lymphoma 2).\n",
    "FASLG (Fas ligand).\n",
    "LEF1 (Lymphoid enhancer-binding factor 1).\n",
    "TCF7 (Transcription factor 7).\n",
    "WNT7A (Wnt family member 7A).\n",
    "\n",
    "\n",
    "## 28. Identification of Biomarkers of Response to IFN-Î³ during Endotoxin Tolerance: Application to Septic Shock\n",
    "\n",
    "Objective:\n",
    "\n",
    "To identify biomarkers that indicate a response to IFN-Î³ (Interferon gamma) treatment during endotoxin tolerance (ET), a feature of sepsis-induced immunosuppression, and validate their diagnostic potential for sepsis patients.\n",
    "\n",
    "\n",
    "1. Study Design:\n",
    "\n",
    "In Vitro ET Model:Peripheral Blood Mononuclear Cells (PBMCs) from healthy donors were cultured with lipopolysaccharides (LPS) to induce ET.\n",
    "Cells were treated with recombinant IFN-Î³ to evaluate its ability to restore immune function.\n",
    "\n",
    "Patient Samples:Whole blood was collected from 7 septic patients within 3 days of ICU admission and from 5 healthy volunteers.\n",
    "Blood was stimulated with LPS Â± IFN-Î³ ex vivo.\n",
    "\n",
    "2. Gene Expression Profiling:\n",
    "\n",
    "Microarray Analysis:Genome-wide expression profiling was performed using Affymetrix U133 Plus chips.\n",
    "Differentially expressed genes (DEGs) were identified under unstimulated, LPS-stimulated, and IFN-Î³-treated conditions.\n",
    "\n",
    "qRT-PCR Validation:Top candidate genes were validated using quantitative real-time PCR in both in vitro and patient samples.\n",
    "\n",
    "3. Biomarker Selection:\n",
    "\n",
    "Identified genes were categorized as:\n",
    "Tolerizable Genes: Downregulated during ET but restored by IFN-Î³.\n",
    "Non-Tolerizable Genes: Upregulated during ET but unaffected by IFN-Î³.\n",
    "\n",
    "Key Findings:\n",
    "\n",
    "1. In Vitro Biomarkers:\n",
    "\n",
    "Tolerizable Genes Restored by IFN-Î³:\n",
    "\n",
    "**TNFAIP6 (Tumor necrosis factor alpha-induced protein 6).\n",
    "GBP1 (Guanylate-binding protein 1).\n",
    "CXCL10 (C-X-C motif chemokine 10)**.\n",
    "\n",
    "Non-Tolerizable Genes Modulated by IFN-Î³:\n",
    "**CXCL5 (C-X-C motif chemokine 5).\n",
    "FCN1 (Ficolin-1).\n",
    "PID1 (Phosphotyrosine interaction domain containing 1)**.\n",
    "\n",
    "2. Validation in Septic Patients:\n",
    "\n",
    "Reduced Expression in Sepsis (Tolerizable Genes):**TNFAIP6, GBP1, and CXCL10** were significantly downregulated in septic patients' blood compared to healthy controls.\n",
    "\n",
    "Their expression levels were restored to normal after IFN-Î³ treatment.\n",
    "\n",
    "Increased Expression in Sepsis (Non-Tolerizable Genes):**CXCL5, FCN1, and PID1** were elevated in septic patients and normalized by IFN-Î³.\n",
    "\n",
    "3. Known Biomarkers Validated:\n",
    "\n",
    "**IL-10 (Interleukin-10)**: Overexpressed in sepsis; reduced by IFN-Î³.\n",
    "\n",
    "**HLA-DRA (MHC class II molecule)**: Downregulated in sepsis; restored by IFN-Î³.\n",
    "\n",
    "Protein vs. Gene Level:The study focuses on gene-level biomarkers, analyzing mRNA expression changes using microarrays and qRT-PCR.\n",
    "\n",
    "Diagnostic and Prognostic Relevance:\n",
    "\n",
    "Diagnostic Role:The identified genes (TNFAIP6, GBP1, CXCL10, CXCL5, FCN1, PID1) can stratify septic patients and identify those who might benefit from IFN-Î³ therapy.\n",
    "\n",
    "Prognostic Role:These biomarkers may serve as tools for monitoring immune reactivation and therapy efficacy in sepsis patients.\n",
    "\n",
    "Conclusion:\n",
    "\n",
    "The study identifies a panel of six novel genes as biomarkers for sepsis-induced immunosuppression. These markers highlight the potential of IFN-Î³ as a therapeutic agent to restore immune function in septic patients. Further large-scale studies are needed to validate these findings and establish clinical utility.\n",
    "\n",
    "Tolerizable Genes Restored by IFN-Î³ (Downregulated in sepsis but normalized by IFN-Î³):\n",
    "TNFAIP6 (Tumor necrosis factor alpha-induced protein 6).\n",
    "GBP1 (Guanylate-binding protein 1).\n",
    "CXCL10 (C-X-C motif chemokine 10).\n",
    "\n",
    "Non-Tolerizable Genes Modulated by IFN-Î³ (Upregulated in sepsis but normalized by IFN-Î³):\n",
    "CXCL5 (C-X-C motif chemokine 5).\n",
    "FCN1 (Ficolin-1).\n",
    "PID1 (Phosphotyrosine interaction domain containing 1).\n",
    "\n",
    "These genes are proposed as diagnostic biomarkers to distinguish septic patients experiencing endotoxin tolerance and to identify those who may respond to IFN-Î³ therapy.\n",
    "\n",
    "\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.16"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
